{"commentary":{"count":45,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":39,"youtube":4,"podcast":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03940235\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"RADIOSA","nct_id":"NCT03940235","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=radiosa-nct03940235. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"RADIOSA","arms":[{"description":"ARM 1: salvage SBRT for lymph nodes and/or bone metastases. All the radiologically documented lesions will be treated simultaneously.","label":"Stereotactic body Radiotherapy (SBRT) only","type":"EXPERIMENTAL"},{"description":"ARM 2: salvage SBRT (as described for ARM 1) + 6-month ADT (luteinizing hormone-releasing hormone (LHRH) agonist or antagonist). ADT should start within one week before the start of SBRT.","label":"Stereotactic body Radiotherapy (SBRT) and hormonotherapy (ADT)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2024-04-01","type":"ESTIMATED"},"conditions":["Oligometastatic Prostate Cancer"],"enrollment":{"count":150,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Androgen deprivation therapy (ADT)","type":"DRUG"},{"name":"SBRT","type":"RADIATION"}],"last_update":"2023-06-28","lead_sponsor":"European Institute of Oncology","official_title":"Radioablation +/- Hormonotherapy for Prostate Cancer Oligorecurrences (RADIOSA Trial): Potential of Imaging and Biology","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2023-12-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS)","timeFrame":"up 3 months from the end of the treatment up to radiological progression within 3 years"}],"references":[{"citation":"Vavassori A, Mauri G, Mazzola GC, Mastroleo F, Bonomo G, Durante S, Zerini D, Marvaso G, Corrao G, Ferrari ED, Rondi E, Vigorito S, Cattani F, Orsi F, Jereczek-Fossa BA. Cyberknife Radiosurgery for Prostate Cancer after Abdominoperineal Resection (CYRANO): The Combined Computer Tomography and Electromagnetic Navigation Guided Transperineal Fiducial Markers Implantation Technique. Curr Oncol. 2023 Aug 28;30(9):7926-7935. doi: 10.3390/curroncol30090576.","pmid":"37754491","type":"DERIVED"},{"citation":"Carloni G, Garibaldi C, Marvaso G, Volpe S, Zaffaroni M, Pepa M, Isaksson LJ, Colombo F, Durante S, Lo Presti G, Raimondi S, Spaggiari L, de Marinis F, Piperno G, Vigorito S, Gandini S, Cremonesi M, Positano V, Jereczek-Fossa BA. Brain metastases from NSCLC treated with stereotactic radiotherapy: prediction mismatch between two different radiomic platforms. Radiother Oncol. 2023 Jan;178:109424. doi: 10.1016/j.radonc.2022.11.013. Epub 2022 Nov 24.","pmid":"36435336","type":"DERIVED"},{"citation":"Marvaso G, Ciardo D, Corrao G, Gandini S, Fodor C, Zerini D, Rojas DP, Augugliaro M, Bonizzi G, Pece S, Cattani F, Mazzocco K, Mistretta FA, Musi G, Alessi S, Petralia G, Pravettoni G, De Cobelli O, Di Fiore PP, Viale G, Orecchia R, Jereczek-Fossa BA. Radioablation +/- hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159). BMC Cancer. 2019 Sep 10;19(1):903. doi: 10.1186/s12885-019-6117-z.","pmid":"31500605","type":"DERIVED"}],"start_date":{"date":"2019-10-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis","url":"https://clinicaltrials.gov/study/NCT03940235"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/radiosa-nct03940235"}